Pharmos Corporation (OTCMKTS:PARS) Files An 8-K Other Events
Item 8.01 Other Events.
The Registrants’s current contact information is listed below:
Address: 3609 Hammerkop Dr., North Las Vegas, NV 89084
Phone number: (415) 841-3570
Email: [email protected]
The Registrant’s President, Secretary, Chief Financial Officer, Chief Executive Officer and Chairman of the Board of Directors is Richard Chiang, who may be reached at the Registrant’s address above.
About Pharmos Corporation (OTCMKTS:PARS)
Pharmos Corporation (Pharmos) is a biopharmaceutical company that discovers and develops therapeutics to treat a range of metabolic and nervous system disorders, including gout, disorders of the brain-gut axis, pain/inflammation and autoimmune disorders. Pharmos owns the rights to both R and S Tofisopam. These are the two enantiomers of racemic tofisopam that has been used outside the United States. The Company’s primary focus is on the development and partnering of Levotofisopam and Dextofisopam. The Company’s product Dextofisopam is used for the treatment of irritable bowel syndrome (IBS). Dextofisopam is the R enantiomer of racemic tofisopam. Levotofisopam is the S-enantiomer of the racemic mixture RS-tofisopam.
